Overview

An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia

Status:
Active, not recruiting
Trial end date:
2026-03-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and activity of acalabrutinib in treating subjects with WM.
Phase:
Phase 2
Details
Lead Sponsor:
Acerta Pharma BV
Treatments:
Acalabrutinib